Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds human MUC16, wherein the first antigen-binding domain that specifically binds human CD28 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3), and wherein the second antigen-binding domain that specifically binds human MUC16 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3);

• wherein the first antigen-binding domain comprises a HCDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 20 and 44;
• wherein HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 22 and 46;
• wherein HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 24 and 48, wherein LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 12 and 36, wherein LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 14 and 38 and wherein LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 16 and 40;
• and
• wherein the second antigen-binding domain comprises a HCDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:
• 4 and 28, wherein HCDR2 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:
• 6 and 30, wherein HCDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:
• 8 and 32, wherein LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 12 and 36, wherein LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 14 and 38 and wherein LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
• 16 and 40.